The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
iPSC Phenotyping Environmental Exposure Program, 2025Screening the Functional Impact of Environmental Chemicals on Human Neurons and Astrocytes in Culture
Study Rationale: With growing global concerns about environmental chemicals acting as a trigger of Parkinson's disease (PD), we will assess the affect such molecules have on the electrical activity...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Characterizing Molecular Subtypes in Parkinson’s Disease and Lewy Body Dementia
Study Rationale: There is currently no disease-modifying treatment for Parkinson’s disease (PD) or Lewy body dementia (LBD). One possible reason is that both of these disorders are highly...
-
Research Grant, 2025Enhancing Recruitment of Individuals Traditionally Underrepresented in Parkinson’s Disease Research into the SPARX3 Clinical Trial
Study Rationale: SPARX3 is a Phase 3 clinical trial designed to assess whether high intensity aerobic exercise can delay progression of Parkinson’s disease (PD) better than does moderate intensity...
-
Research Grant, 2025Evaluation of Novel PET Probes for Alpha-synuclein Imaging
Study Rationale: Aggregation of the protein alpha-synuclein into fibrils in Lewy bodies and Lewy neurites is the key pathological feature of Parkinson's disease (PD) and related synucleinopathies...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Assessing the Aggregation of Alpha-synuclein Across Aging, Alzheimer’s Disease and Dementia with Lewy Bodies
Study Rationale: Forms of alpha-synuclein, the protein that aggregates in Parkinson’s disease (PD), can be detected in cerebrospinal fluid (CSF) by seed amplification assays (SAA). These highly...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2025Development of an Assay for Rapid Detection of Activated LRRK2
Study Rationale: Mutations associated with Parkinson’s disease (PD) elevate the activity of a protein called Leucine-rich repeat kinase 2 (LRRK2). Kinases add phosphate groups to other proteins and to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.